Premium
Blocking interleukin‐1β in acute and chronic autoinflammatory diseases
Author(s) -
Dinarello C. A.
Publication year - 2011
Publication title -
journal of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 160
eISSN - 1365-2796
pISSN - 0954-6820
DOI - 10.1111/j.1365-2796.2010.02313.x
Subject(s) - medicine , immunology , nalp3 , anakinra , gout , interleukin 6 , disease , inflammation , inflammasome
. Dinarello CA (Department of Medicine, University of Colorado, Aurora, CO, USA). Blocking interleukin‐1β in acute and chronic autoinflammatory diseases. (Key Symposium) J Intern Med 2011; 269 : 16–28. An expanding spectrum of acute and chronic inflammatory diseases is considered ‘autoinflammatory’ diseases. This review considers autoinflammatory diseases as being distinct from ‘autoimmune’ diseases. Autoimmune diseases are associated with dysfunctional T cells and treated with ‘biologicals’, including antitumour necrosis factorα, CTLA‐Ig, anti‐IL‐12/23, anti‐CD20, anti‐IL‐17 and anti‐IL‐6 receptor. In contrast, autoinflammatory diseases are uniquely attributed to a dysfunctional monocyte caspase 1 activity and secretion of IL‐1β; indeed, blocking IL‐1β results in a rapid and sustained reduction in the severity of most autoinflammatory diseases. Flares of gout, type 2 diabetes, heart failure and smouldering multiple myeloma are examples of seemingly unrelated diseases, which are uniquely responsive to IL 1β neutralization.